<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767492</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048698</org_study_id>
    <nct_id>NCT02767492</nct_id>
  </id_info>
  <brief_title>Steroid Injection vs. BioDRestore for Patients With Knee OA</brief_title>
  <official_title>A Double-blind, Randomized Study Comparing Steroid Injection and BioDRestore for Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hawkins Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integra LifeSciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hawkins Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will include patients who are diagnosed with knee OA and are recommended for a
      knee injection. Study subjects will be randomized to receive either the standard of care knee
      injection (steroid) or amniotic tissue injection (BioDRestore). Study subjects will be asked
      for permission for a baseline knee aspiration prior to the knee injection. At 6 months
      post-injection, knee aspirations will be taken and sent for analysis. Study subjects will be
      followed for 1 year post-injection to include range of motion measurements and
      patient-reported pain/functional outcome measurements. X-rays will also be taken at the
      1-year post-injection appointment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient reported level of pain</measure>
    <time_frame>12 months</time_frame>
    <description>Pain assessed via Visual Analog Score (VAS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported overall quality of life measures</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life assessed via Veterans RAND 12 Item Health Survey (VR-12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee function</measure>
    <time_frame>12 months</time_frame>
    <description>Knee function assessed via Lysholm Knee Score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Normalcy</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of normal for affected knee assessed via Single Assessment Numeric Evaluation (SANE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee Outcome Measure</measure>
    <time_frame>12 months</time_frame>
    <description>Knee outcome measure assessed via Knee Injury and Osteoarthritis Outcome Score (KOOS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>6 months</time_frame>
    <description>Inflammatory markers in synovial fluid of affected knee.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>BioDRestore™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioD Restore</intervention_name>
    <description>Investigational product, BioD Restore, will be injected into the articular space of the knee.</description>
    <arm_group_label>BioDRestore™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kenalog</intervention_name>
    <description>Active comparator, Kenalog steroid, will be injected into the articular space of the knee.</description>
    <arm_group_label>Corticosteroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 to 80 years.

          -  Willing and able to give voluntary informed consent to participate in this
             investigation.

          -  Patient presents with knee osteoarthritis and Kellgren Lawrence grade 2-4 (OA
             diagnosed and confirmed by treating physician using standing x-ray).

          -  Candidate for intra-articular knee injection.

          -  BMI &lt; 40

        Exclusion Criteria:

          -  Patients who have received intra-articular injection(s) in the last 3 months.

          -  Patients who have undergone arthroscopic surgery on the study knee in the past year.

          -  Patients who have undergone arthroplasty on the study knee.

          -  Ligament instability

          -  Diabetes (Type 1 or II)

          -  Inflammatory arthropathies.

          -  Fibromyalgia or chronic fatigue syndrome.

          -  Female patient who is pregnant or nursing.

          -  Chronic use of narcotics.

          -  Any other reason (in the judgment of the investigator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Siffri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steadman Hawkins Clinic of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone Acetonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

